Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Hao Xie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9640-4055; OpenAlex author ID A5040290239. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology. Co-author DOI 10.1080/14740338.2025.2469273↗
  2. Splenic-vasculature involvement is associated with poor prognosis in resected distal pancreatic cancer. Co-author DOI 10.1093/gastro/goaa084↗
  3. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000708↗
  4. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0086↗
  5. Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. Co-author DOI 10.4292/wjgpt.v11.i2.25↗
  6. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. First author DOI 10.1097/coc.0000000000000492↗
  7. The Management of Older Adults with Pancreatic Adenocarcinoma. First author DOI 10.3390/geriatrics3040085↗
  8. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.27715↗
  9. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarc… Co-author DOI 10.1369/0022155412468137↗
  10. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma. Co-author PMID 22670179↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiang Xu · 1 shared paper, 2026 · strength 0.43
  2. Wenming Wu · 1 shared paper, 2026 · strength 0.43
  3. Wen Wee Ma · 4 shared papers, 2018–2020 · strength 0.40
  4. Joleen Marie Hubbard · 3 shared papers, 2018–2020 · strength 0.32
  5. John R. Ogden · 3 shared papers, 2018–2020 · strength 0.32
  6. Wei Jiang · 5 shared papers, 2012–2021 · strength 0.32
  7. Xiuli Liu · 3 shared papers, 2013–2021 · strength 0.23
  8. Aminah Jatoi · 2 shared papers, 2020 · strength 0.21
  9. Tanios Bekaii‐Saab · 2 shared papers, 2020 · strength 0.21
  10. Gloria M. Petersen · 2 shared papers, 2020 · strength 0.21
  11. Robert R. McWilliams · 2 shared papers, 2020 · strength 0.21
  12. Amit Mahipal · 2 shared papers, 2020 · strength 0.21
  13. Teena Dhir · 2 shared papers, 2020–2021 · strength 0.19
  14. Christopher William Schultz · 2 shared papers, 2020–2021 · strength 0.19
  15. Richard Zheng · 2 shared papers, 2020–2021 · strength 0.19
  16. Xuefeng Zhang · 2 shared papers, 2020–2021 · strength 0.19
  17. Bing Ren · 2 shared papers, 2020–2021 · strength 0.19
  18. Feng Yin · 2 shared papers, 2020–2021 · strength 0.19
  19. Mark Joseph Truty · 1 shared paper, 2020 · strength 0.10
  20. Xiuli Liu · 2 shared papers, 2012–2013 · strength 0.09
  21. Alex A. Adjei · 1 shared paper, 2019 · strength 0.08
  22. Robert M. Straubinger · 1 shared paper, 2019 · strength 0.08
  23. Renuka V. Iyer · 1 shared paper, 2019 · strength 0.08
  24. Shu‐Yuan Xiao · 1 shared paper, 2013 · strength 0.05
  25. Richard Kim · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.